Circulating immune complexes (CIC) were isolated from serum samples from patients with bacteremic and nonbacteremic pneumococcal pneumonia. Overall, 63% (26 of 41) of patients with pneumococcal pneumonia had elevated levels of immunoglobulin G (IgG)-containing CIC. IgM-containing CIC were identified in samples from only three patients. Serum samples from nonbacteremic patients contained significantly higher levels of ,ug/mI) than did samples from bacteremic patients (31.7 + 26.9 ,ug/ml) during week 1 in hospital (P < 0.05). Immune complex levels did not correlate with IgG concentrations in serum or anticapsular antibody levels. Immune complexes from nonbacteremic patients had sedimentation coefficients of >19s by density gradient ultracentrifugation. In contrast, CIC from bacteremic patients had smaller coefficients, of between 9s and 14s. Pneumococcal capsular antigens were identified in concentrated, dissociated CIC from both patient groups by counterimmunoelectrophoresis.
Streptococcus pneumoniae is a frequent cause of community-acquired pneumonia, bacteremia, and meningitis in elderly people. Mortality due to pneumococcal infections has changed little in the last two decades. Austrian and Gold (2) in 1964 and authors of several recent studies (17, 20, 33, 34) have reported 20 to 70% mortality from bacteremic pneumococcal pneumonia. Factors associated with increased probability of death include an age of -60 years, multilobar pneumonia, a total leukocyte count of <5,000/mm3, preexisting chronic illnesses, and the presence of meningitis or other suppurative complications of pneumonia. Antimicrobial chemotherapy has improved survival over that in the preantibiotic era. However, despite antibiotic therapy, nearly 20% of patients with uncomplicated pneumococcal bacteremia die, often within 24 h of hospitalization. Recent advances in intensive-care medicine have failed to increase the survival rate of patients with pneumococcal bacteremia (20) .
Although penicillin remains the drug of choice for patients with pneumococcal infections, death often occurs before therapy can influence the course of disease. Death may result from irreversible injury to the patient prior to administration of effective, bactericidal antibiotics (1, 2, 20). Despite increasing knowledge of pneumococcal virulence factors and host response to infection, the precise mechanism by which pneumococci cause death is unknown (21, 35) .
Circulating immune complexes (CIC) have been identified in the sera of patients with severe pneumococcal infections (22, 25, 31, 40, 41 ; G. Schiffman, J. E. Summerville, R. Castagna, R. Douglas, M. J. Bonner, and R. Austrian, Fed. Proc. 33:758, 1974 ). However, host and bacterial components of CIC in pneumococcal infections have not been well studied. These limitations have prevented direct assessment of the pathogenic significance of CIC in pneumococcal disease. The purpose of this study was to determine the incidence and presence of pneumococcal antigens in the CIC of patients with bacteremic and nonbacteremic pneumococ-* Corresponding author.
cal pneumonia. For immune complex detection we used a unique reagent, an equine rheumatoid Clq-like protein complex (RhC) originally described by McDonald (28) , which binds to and coprecipitates immune complexes. Detection of CIC with this reagent is independent of the concentration of monomeric immunoglobulins in serum and does not require an artificial standard such as aggregated human globulin for obtaining quantitative data (28) . CIC levels were determined by quantifying the amount of immunoglobulin G (IgG) or IgM in RhC-precipitated materials by radial immunodiffusion (27) Isolation of CIC from serum. Immune complexes were isolated from serum samples from infected patients or normal control volunteers by coprecipitation with equine RhC (13) . This coprecipitation is independent of complement activation and of the amount of monomeric IgG in the test serum. Prior to CIC coprecipitation, lipids were extracted from serum by mixing 0.25 ml of serum with 0.75 ml of 1,1,2-trichlorotrifluoroethane. After centrifugation, 0.1 ml of extracted serum was mixed with 0.4 ml of a 1-mg/ml solution of RhC in polystyrene tubes and incubated at 37°C for 15 min. Tube contents were then dialyzed against 2 liters of 0.05 M Tris hydrochloride-0.01 M EDTA buffer (pH 8.2) for 1 h at room temperature. Under these buffer conditions, RhC binds to and precipitates immune complexes. The RhC-CIC precipitate was washed twice with dialyzing buffer and dissolved in 0.1 ml of 0.1% sodium dodecyl sulfate in PBS. The antibody content of the dissociated immune complexes was measured by radial immunodiffusion in the manner described above. A positive CIC test for IgG antibody (IgG-CIC) was defined as >25 ptg/ml, which was the mean for 15 normal serum samples plus 2 standard deviations. A positive test for IgM antibody (IgM-CIC) was >22 Kg/ml.
Raji cell assay. For comparison purposes, CIC were also determined for 60 selected sera by the Raji cell immunoassay, as described by Theofilopoulos et al. (45) . A positive Raji test for CIC was defined as 20 pg of aggregated human globulin equivalents per ml (mean of controls plus 2 standard deviations).
Antigen analysis of CIC. Five serum samples with high levels of IgG-CIC were selected for further analysis. Samples 1 and 2, from bacteremic patients, contained 95 and 86
Kg of IgG-CIC per ml, respectively. Samples 3, 4, and 5, from nonbacteremic patients, contained 480, 401, and 460 Kug of IgG-CIC per ml, respectively. None of these patients had detectable levels of free PCP in their serum by CIE. To identify pneumococcal capsular antigens within CIC, immune complexes were purified and concentrated by the following modification of the RhC coprecipitation method. Serum (2 ml) was added to 8 ml of RhC (1 mg/ml), mixed, and incubated for 30 min at 37°C. CIC were precipitated by dialysis against Tris-EDTA buffer as described above. However, after two washes, the precipitated material was dissolved in only 40 ,u of 0.1% sodium dodecyl sulfate to effect a 50-fold concentration of CIC. These purified, dissociated CIC were analyzed for PCP by CIE with antiserum specific for the pneumococcal serotype of each patient. Serotypes were as follows: patient 1, serotype 11; patient 2, serotype 9; patient 3, serotype 6; and patients 4 and 5, serotype 3.
Sucrose density gradient ultracentrifugation. The relative molecular size of CIC in serum samples from selected patients was determined by density gradient ultracentrifugation (5, 6) . Control and test samples were diluted 1:2, and 0.5 ml of each sample was applied to the top of a 10-ml linear sucrose gradient (10 to 37%) prepared in PBS. Centrifugation was performed with an 50.2 Ti rotor (Beckman Instruments, Inc., Fullerton, Calif.) at 4°C for 6.5 h at 220,000 x g. Reference markers were 7s IgG and 19s IgM. After centrifugation, 0.5-ml samples were collected from the top of the gradients, and 0.1 ml of each fraction was assayed in duplicate for the presence of CIC by RhC coprecipitation.
RESULTS
Patients. Clinical characteristics of the patients in this study are shown in Table 1 . Underlying diseases included ethanol abuse in 21, chronic obstructive pulmonary disease in 24, organic heart disease in 18, diabetes mellitus in 3, peptic ulcer disease in 6, and osteoarthritis in 4. Three patients had fatal infections. Compared with the bacteremic group, nonbacteremic patients were older (mean age, 60.2 versus 71.0 years; range, 42 to 83 versus 53 to 92; P < 0.01, Wilcoxson rank sum test) and had a higher incidence of chronic obstructive lung disease (70 versus 27%; P < 0.01). There were no differences in ethanol abuse, infecting pneumococcal serotypes, or the number of fatal infections between bacteremic and nonbacteremic patient groups. Of the 35 pneumococcal isolates which were available for serotyping, 33 (95%) are contained in the commercially available 23-valent pneumococcal vaccine. Only 1 of 41 patients had received the pneumococcal vaccine.
Comparison of RhC with the Raji cell assay. The RhC assay was compared with the Raji cell assay in a double-blind study of 60 serum specimens from patients. Overall, there was a high correlation (92%, 55 of 60) when the two assays were compared for detecting positive CIC-containing samples (Table 2 ). The RhC reagent detected elevated CIC levels in 37 of the 40 Raji-positive serum samples (93% agreement). Of the 20 samples which were negative by the Raji assay, 18 were also negative by RhC (90% agreement).
Although there was good correlation between Raji and the RhC assays in detecting positive and negative sera, the two assays did not agree on the amount of CIC in several of the serum samples. There was no obvious pattern in the differences; i.e., five samples that contained >200 ,ug/ml by the RhC assay were positive at the lower limit of the Raji assay, but four samples that were high by the Raji test were much lower in the RhC assay, which could indicate that the RhC and Raji assays measure different types of CIC. Because the RhC assay is nonradioactive, provides specific immunoglobulin data, and is more economical than the Raji assay, the RhC assay was used for this study.
CIC. A total of 63% of serum samples from patients were positive for IgG-CIC during hospitalization (Table 3 ). Both bacteremic and nonbacteremic patients demonstrated an acute rise in IgG-CIC levels, which persisted through week 3. Significant differences between patient groups were not noted at any of the weekly time intervals. Of 27 patients with positive sera, 22 (82%) had peak CIC levels after day 7 in hospital. IgM-CIC occurred in samples from only one bacteremic patient and two nonbacteremic patients (data not shown).
Although IgG-CIC occurred with similar frequency in bacteremic and nonbacteremic patients, the concentration of IgG-CIC was markedly different between the two patient groups and the controls (Table 4) . Pneumonia patients had higher concentrations of IgG-CIC than controls at all times (P < 0.05, Student's t test), except for the bacteremic group at days 1 to 3. Nonbacteremic patients had higher levels of IgG-CIC than bacteremic patients during week 1 (P < 0.05). The differences in CIC levels between patient groups at weeks 2 and 3 approached but did not reach statistical significance (P < 0.10). CIC levels in samples from several nonbacteremic patients exceeded 300 jig of IgG per ml.
There was no correlation between the presence of CIC and IgG levels in serum. Our number of patients was too small to correlate the presence or the levels of CIC with clinical outcome. However, of three patients who died, one patient with bacteremia was negative for IgG-CIC and the two patients with fatal nonbacteremic infections had peaks of 168 and 301 ,ug of IgG-CIC/ml of serum.
Antibody response. The homotypic serologic response of patients infected with S. pneumoniae is summarized in ent fractions were assayed for IgG-CIC by RhC coprecipitation. Serum samples from nonbacteremic patients contained RhC-reactive material in fractions with a coefficient of sedimentation of >19s. Control specimens showed a very small peak of reactive material in this region. In contrast, bacteremic serum samples contained intermediate-sized CIC, which sedimented in the 9s to 14s region. The sample from bacteremic patient 2 also demonstrated some reactivity in the >19s region. Identification of pneumococcal capsular antigens in purified CIC. RhC-reactive materials from 2-ml samples of IgG-CICpositive and negative sera were concentrated 50-fold and dissociated with sodium dodecyl sulfate. Concentrated immune complexes were tested for the presence of pneumococcal capsular antigen by CIE with specific anticapsular antiserum. CIE yielded strong precipitin bands to type- specific antisera for four of five patients, indicating the presence of pneumococcal capsular antigen within the immune complexes. The serum sample from bacteremic patient 2 was also positive for capsular antigen, with a less pronounced precipitin band. CIC reacted only with antiserum specific for the pneumococcal isolate from the patient. Precipitation was absent from the IgG-CIC negative serum sample tested against Omni or serotype-specific antisera. To rule out RhC concentration of free PCP, CIC-negative serum was spiked with 10 ,ug of type 3 PCP per ml, precipitated with RhC, and concentrated as above. No precipitation band was detected after CIE against type 3 antiserum, indicating that only CIC-bound PCP was coprecipitated with RhC. DISCUSSION Our studies demonstrate that most patients with bacteremic or nonbacteremic pneumococcal pneumonia have elevated levels of CIC. The finding of CIC in serum samples from 63% of pneumonia patients is in accord with results of earlier studies (40; Schiffman et al., Fed. Proc., 1974). Immune complexes were of the IgG class; IgM-containing complexes were detected in samples from only 3 of 41 patients. Although the incidence of elevated CIC was the same for both patient groups, bacteremic patients had significantly lower levels of CIC than nonbacteremic patients did. Reasons for diminished levels of CIC in bacteremic patients are speculative. It is apparent that an early and effective antipneumococcal response does not occur in bacteremic patients, as indicated by their inability to limit pneumococcal dissemination. Pneumococcal bacteremia and The assays used for CIC determination in prior studies depend on the complement-activating properties of CIC, cryoprecipitation, or detection of complexed IgG with antiimmunoglobulins (25, 31, 40) . In this study, CIC were precipitated from test specimens by a unique reagent, RhC, and quantified by determining the amount of complexed immunoglobulin by using radial immunodiffusion. RhC demonstrated a high correlation for both positive and negative sera in the Raji cell assay, a well established method for CIC detection. RhC has been used by others for analysis of IgG-, IgM-, and IgA-containing CIC in diabetic animals (30), mice with various malignancies (29) , and children with cystic fibrosis (13) . RhC is stable when stored below 0°C and has been shown to be highly efficient, reproducible, and independent of serum immunoglobulin.
Our findings of elevated IgG-CIC levels in both patient populations prompted us to isolate and purify CIC in the hope that preliminary characterization of individual components of those materials would provide insight into their significance. Such an approach was necessary because CIC assays are not antigen specific and provide only indirect evidence for immune complex-mediated pathogenicity (4, 23) . Density gradient ultracentrifugation showed that CIC from nonbacteremic patients were found mainly in or above the 19s range, which is consistent with sedimentation coefficients ofCIC found in samples from patients with other infectious diseases (5, 9, 47 (8, 11, 41) . More recent reports (22, 25, 39, 40) provide immunofluorescence and electron microscopic evidence of immune complex nephritis following pneumococcal infections. In 1978, Kaehny et al. (25) reported pulmonary alveolitis and nephritis following pneumococcal pneumonia. Immunoglobulins, complement, and pneumococcal capsular antigen were identified in the serum cryoprecipitate, alveolar walls, and capillary basement membranes of this patient. Rytel and Preheim (40) reported elevatedCIC levels in half of their patients with bacteremic pneumococcal pneumonia, which correlated directly with disease morbidity, as measured by severity of pneumonia, duration of fever, and length of hospital stay. These authors suggest that the immune complexes formed during pneumococcal infections contribute to lung damage via complement and neutrophil activation. This mechanism has been demonstrated in other settings of pulmonary injury (14, 24, 32) . Autopsy studies to document pneumococcal CIC in lung tissue have not been reported.
We identified pneumococcal capsular antigens in isolated, sodium dodecyl sulfate-dissociated complexes. All five bacteremic and nonbacteremic serum samples with high levels of CIC were positive for pneumococcal capsular antigens by CIE against specific capsular typing sera. It has been reported that some typing sera may be contaminated with antibodies against the C polysaccharide, a cell wall antigen common to all pneumococci (42) . Such antibodies react with both homologous and heterologous strains of pneumococci by CIE. We did not detect any cross-reactivity between our typing sera and heterologous pneumococci or PCP. When concentrated CIC were tested against homologous and heterologous antisera, precipitation bands occurred only with homologous serum, indicating the presence of the capsular polysaccharide.
The data on antigenicity and protective effects of natural S. pneumoniae infections in adults are limited. Type-specific antibody responses to pneumococcal pneumonia have been noted to be extremely variable (19) and often transient (16, 43) . These transient responses have been associated with recurrences of pneumonia. In our study, 12 of 24 (50%) tested patients developed a -twofold rise in antibody titer to their infecting serotype, with 9 of 24 (38%) developing a fourfold rise in antibody titer. Berntsson et al. (7), using a tube ELISA and a mixture of six capsular polysaccharide antigens, found a > 100% rise in the IgG level in 14 of 17 patients with pneumococcal pneumonia. However, these results were not confirmed by others. Coonrod and Drennan, using indirect hemagglutination (10), Riley and Douglas, using a radioimmunoassay (36) , and Kalin and Lindberg, using an ELISA (26) , have shown that the antibody levels to homologous capsular polysaccharide in many patients fail to increase after natural infection. Although it is difficult to compare studies which involve the use of different antibody detection methods, our results are in agreement with those of most earlier work. The failure of natural infection to elicit antibodies may be due to the release of soluble antigen from infected tissue into the circulation. Free antigen may neutralize antibodies byCIC production (39) or cause immunologic paralysis by antigen excess (18) . This could explain the low and variable titers reported by us and others. The persistence ofCIC may also have contributed to the poor antigenicity of S. pneumoniae in our patients (38) .
This study does not resolve the role ofCIC in pneumococcal infections. It confirms that in patients with pneumococcal pneumonia, someCIC represent a response to stimulation with pneumococcal capsular antigen and are not simply an autoregulatory phenomenon of the immune system (37) . This study also demonstrates the ability of RhC to isolate CIC from human serum in sufficient quantity and purity to permit detailed analysis of their characteristics and components.
